Literature DB >> 20547182

Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Ashiwel S Undieh1.   

Abstract

Dopamine D(1)-like receptors consisting of D(1) and D(5) subtypes are intimately implicated in dopaminergic regulation of fundamental neurophysiologic processes such as mood, motivation, cognitive function, and motor activity. Upon stimulation, D(1)-like receptors initiate signal transduction cascades that are mediated through adenylyl cyclase or phosphoinositide metabolism, with subsequent enhancement of multiple downstream kinase cascades. The latter actions propagate and further amplify the receptor signals, thus predisposing D(1)-like receptors to multifaceted interactions with various other mediators and receptor systems. The adenylyl cyclase response to dopamine or selective D(1)-like receptor agonists is reliably associated with the D(1) subtype, while emerging evidence indicates that the phosphoinositide responses in native brain tissues may be preferentially mediated through stimulation of the D(5) receptor. Besides classic coupling of each receptor subtype to specific G proteins, additional biophysical models are advanced in attempts to account for differential subcellular distribution, heteromolecular oligomerization, and activity-dependent selectivity of the receptors. It is expected that significant advances in understanding of dopamine neurobiology will emerge from current and anticipated studies directed at uncovering the molecular mechanisms of D(5) coupling to phosphoinositide signaling, the structural features that might enhance pharmacological selectivity for D(5) versus D(1) subtypes, the mechanism by which dopamine may modulate phosphoinositide synthesis, the contributions of the various responsive signal mediators to D(1) or D(5) interactions with D(2)-like receptors, and the spectrum of dopaminergic functions that may be attributed to each receptor subtype and signaling pathway. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547182      PMCID: PMC2939266          DOI: 10.1016/j.pharmthera.2010.05.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  350 in total

1.  Mammal-like striatal functions in Anolis. II. Distribution of dopamine D(1) and D(2) receptors, and a laminar pattern of basal ganglia sub-systems.

Authors:  E C Clark; L R Baxter; L S Dure; R F Ackermann; G F Kemp; S E Bachus
Journal:  Brain Behav Evol       Date:  2000-11       Impact factor: 1.808

2.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.

Authors:  Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten
Journal:  Nat Neurosci       Date:  2007-02-04       Impact factor: 24.884

Review 3.  Catecholamine regulation of the prefrontal cortex.

Authors:  A F Arnsten
Journal:  J Psychopharmacol       Date:  1997       Impact factor: 4.153

4.  Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).

Authors:  A Brunet; J Park; H Tran; L S Hu; B A Hemmings; M E Greenberg
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

5.  In vivo regulation of central nervous system progesterone receptors: cocaine induces steroid-dependent behavior through dopamine transporter modulation of D5 receptors in rats.

Authors:  E M Apostolakis; J Garai; J H Clark; B W O'Malley
Journal:  Mol Endocrinol       Date:  1996-12

6.  Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation.

Authors:  F J Monsma; L C Mahan; L D McVittie; C R Gerfen; D R Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.

Authors:  D Ghosh; S E Snyder; V J Watts; R B Mailman; D E Nichols
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

8.  Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal.

Authors:  Samuel P Lee; Christopher H So; Asim J Rashid; George Varghese; Regina Cheng; A José Lança; Brian F O'Dowd; Susan R George
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

9.  Characterization of subtype-specific antibodies to the human D5 dopamine receptor: studies in primate brain and transfected mammalian cells.

Authors:  C Bergson; L Mrzljak; M S Lidow; P S Goldman-Rakic; R Levenson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Synergistic effects of inositol 1,3,4,5-tetrakisphosphate on inositol 2,4,5-triphosphate-stimulated Ca2+ release do not involve direct interaction of inositol 1,3,4,5-tetrakisphosphate with inositol triphosphate-binding sites.

Authors:  J W Loomis-Husselbee; P J Cullen; U E Dreikausen; R F Irvine; A P Dawson
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

View more
  38 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Dopamine-sensitive signaling mediators modulate psychostimulant-induced ultrasonic vocalization behavior in rats.

Authors:  Stacey N Williams; Ashiwel S Undieh
Journal:  Behav Brain Res       Date:  2015-08-11       Impact factor: 3.332

3.  Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.

Authors:  Zhi Gen Leng; Shao Jian Lin; Ze Rui Wu; Yu Hang Guo; Lin Cai; Han Bing Shang; Hao Tang; Ya Jun Xue; Mei Qing Lou; Wenxiu Zhao; Wei-Dong Le; Wei Guo Zhao; Xun Zhang; Zhe Bao Wu
Journal:  Autophagy       Date:  2017-06-14       Impact factor: 16.016

Review 4.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  The Potential of Cannabinoid-Based Treatments in Tourette Syndrome.

Authors:  Bekir B Artukoglu; Michael H Bloch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

7.  Dopamine Neurotransmission in the Ventral Tegmental Area Promotes Active Forgetting of Cocaine-Associated Memory.

Authors:  Fernando Castillo Díaz; Micaela A Hernandez; Tomas Capellá; Jorge H Medina
Journal:  Mol Neurobiol       Date:  2019-02-09       Impact factor: 5.590

8.  Dopamine in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory.

Authors:  Cecilia P Kramar; Vladimir I Chefer; Roy A Wise; Jorge H Medina; M Flavia Barbano
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

9.  Dopamine increases HIV entry into macrophages by increasing calcium release via an alternative signaling pathway.

Authors:  E A Nickoloff-Bybel; P Mackie; K Runner; S M Matt; H Khoshbouei; P J Gaskill
Journal:  Brain Behav Immun       Date:  2019-08-27       Impact factor: 7.217

10.  Structure of distress call: implication for specificity and activation of dopaminergic system.

Authors:  Subramanian Mariappan; Wieslaw Bogdanowicz; Hanumanthan Raghuram; Ganapathy Marimuthu; Koilmani Emmanuvel Rajan
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2015-11-26       Impact factor: 1.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.